FAH and tyrosinemia: ,192 Yin et al employed LNPs to deliver Cas9 mRNA, AAV encoding sgRNA, and DNA templates to mice to rectify fumarylacetoacetate hydrolase (Fah)-splicing mutation while treating tyrosinemia and achieved 6% correction.193